Ki67、P53、VEGF和C-erbB-2在乳腺癌组织中表达的相关性研究及其临床意义

被引：112

作者：

李宝江

朱志华

王军业

侯景辉

赵进明

张蓬原

姚广裕

王曦

龙浩

杨名添

戎铁

机构：

[1] 华中山大学肿瘤防治中心胸科,华中山大学肿瘤防治中心胸科,华中山大学肿瘤防治中心胸科,华中山大学肿瘤防治中心胸科,华中山大学肿瘤防治中心胸科,华中山大学肿瘤防治中心胸科,华中山大学肿瘤防治中心胸科,华中山大学肿瘤防治中心胸科,华中山大学肿瘤防治中心胸科,华中山大学肿瘤防治中心胸科,华中山大学肿瘤防治中心胸科广东广州,广东广州,广东广州,广东广州,广东广州,广东广州,广东广州,广东广州,广东广州,广东广州,广东广州

来源：

癌症 | 2004年 / 10期

基金：

国家科技攻关计划;

关键词：

乳腺癌; 细胞增殖抗原Ki67; P53; 血管内皮生长因子(VEGF);

D O I：

暂无

中图分类号：

R737.9 [乳腺肿瘤];

学科分类号：

100214 ;

摘要：

背景与目的:细胞增殖抗原标记物(Ki67)为细胞增殖的一个重要生物学指标。本研究旨在探讨Ki67、P53、VEGF和C-erbB-2在乳腺癌组织中的表达及其与临床病理因素的相关性。方法:用免疫组化方法检测151例乳腺癌组织中Ki67和其他生物学指标的表达,并与临床病理因素进行相关性分析。结果:Ki67在乳腺癌组织中的阳性率为74.8%(113/151)。Ki67表达与乳腺癌临床分期有关(P<0.05),而与患者年龄、肿瘤大小、淋巴结转移状况无显著性相关(P>0.05);Ki67表达与P53、C-erbB-2表达呈正相关(P<0.05),而与VEGF表达无显著性相关;Ki67和VEGF的共表达与肿瘤大小和临床分期有关(P<0.05)。结论:Ki67阳性表达可作为评价乳腺癌发生、发展的生物学指标,联合VEGF检测更有助于乳腺癌临床分期的判断。

引用

页码：1176 / 1179

页数：4

共 13 条

[1]

Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Volpert OV,Dameron KM,Bouck N. Oncegene . 1997

[2]

Immunohistochemical expression of P53, nm23-HI, Ki67 and DNA ploidy;correlation with lymph node status and other clinical pathologic parameters in breast cancer. Midulla C,De Iorio P,Nagar C,etal. Anticancer Research . 1999

[3]

HER-2 expression and cell proliferation: prognostic markers in patients with node-negative breast cancer. Volpi A,Nanni O,De Paola F. Journal of Clinical Oncology . 2003

[4]

Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Gerdes J,Schwab U,Lemke H,et al. International Journal of Cancer . 1983

[5]

Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. Hall PA,Levison DA,Woods AL,et al. Journal of Paleopathology . 1990

[6]

Proliferation and p53 expression in anal cancer precursor lesions. Mullerat J,Deroide F,Winslet MC,et al. Anticancer Research . 2003

[7]

Predictive value of thefraction of cancer cells immunolabeled for proliferatingcell nuclear antigen or Ki67 in biopsies of head and neckcarcinomas to identify lymph node metastasis:compari-son with clinical and radiologic examinations. Liu M,Lawson G,Delos M,et al. Head and Neck Journal for the Sciences and Space of the Head and Neck . 2003

[8]

Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki-67. Tut VM,Braithwaite AL,Angus B, et al. British Journal of Cancer . 2001

[9]

Prognos-tic significance ofimmunohisto-chemicallylocalized biomarkers in stageⅡand stageⅢbreast cancer:a multivariate analysis. BHATAVDEKAR J M,PATELD D,SHAHNG,et al. Annals of Surgical Oncology . 2000

[10]

Proliferationm arkers pred ictive of the pathological response and d iseaseoutcom e of patients w ith breast carc inom as treated by anthra-cyc line-based preoperative chemotherapy. V incent-Salomon A,Rousseau A,Jouve M,et a l. European Journal of Cancer . 2004

← 1 2 →